An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.
In 1994, 630 Gambian infants were immunized with three doses of the synthetic polypeptide malaria vaccine SPf66 or with a control vaccine. No significant protection against first or total attacks of malaria was observed among the children who received SPf66. However, the period of follow-up was short. Thus, 532 children were followed for a second malaria transmission season during which 291 episodes of malaria were detected. Protective efficacies of SPf66 against first attacks of malaria and against all attacks of malaria were 8% [95% CI-20%, 30%] and 2% [95% CI-26% 24%] respectively. SPf66 did not provide any significant degree of protection to Gambian infants during a second year of follow-up.
Bojang
K A
KA
Medical Research Council Laboratories, Fajara, The Gambia.
Obaro
S K
SK
D'Alessandro
U
U
Bennett
S
S
Langerock
P
P
Targett
G A
GA
Greenwood
B M
BM
D000818:Animals; D005260:Female; D005500:Follow-Up Studies; D005714:Gambia; D006801:Humans; D007223:Infant; D017780:Malaria Vaccines / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D010963:Plasmodium falciparum; D015800:Protozoan Proteins; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011994:Recombinant Proteins; C066269:SPf66 protein, Plasmodium; D014614:Vaccines, Synthetic